Prosensa Holding N.V. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (30)

Latest Posts

About This Stock More About This Stock
Building Products Maker Azek Surges In Debut
Article By: The Fly
Sunday, June 14, 2020 2:18 PM EST
After opening higher, building products maker Azek ended its first trading day up over 18%. The company raised about $765 million in the biggest initial public offering of the week.
In this article: RNA Also: BAC, GS, WFC, VXX, JEF, TREX, CS, LLY, COWN, SIVB, JPM, MS, EVR, RPRX, ADCT
Read
E Shares Of Prosensa Surge 50% After Announcing It Will Be Acquired By Biomarin
Article By: Terry Chrisomalis
Monday, November 24, 2014 10:33 AM EST
Biomarin is purchasing Prosensa for approximately $840 million.
In this article: BMRN, RNA, SRPT, RGLS
Read
Sarepta Hits Another Roadblock Prior To Eteplirsen New Drug Application
Article By: Jake King
Monday, October 27, 2014 5:32 PM EST
On Monday morning, Sarepta Therapeutics (SRPT) held a teleconference concerning regulatory updates for Eteplirsen, the company's lead drug candidate for Duchenne Muscular Dystrophy.
In this article: RNA, SRPT
Read
EC ROTH Capital's Debjit Chattopadhyay: Marriage Of Diagnostics To New Therapies Breeds Biotech Winners
Article By: The Life Sciences Report
Wednesday, September 24, 2014 4:53 PM EST
A medical researcher turned biotech analyst highlights several companies with unique diagnostic and therapeutic technologies.
In this article: BAX, CVD, DGX, NGNM, RHHBY, INCY, CTIC, RNA, SRPT
Read
EC Sarepta Tumbles On New Drug Data But Presents A Big Buying Opportunity
Article By: Terry Chrisomalis
Monday, July 14, 2014 3:25 PM EST
Shares of Sarepta Therapeutics (SRPT) tumbled as much as 28% after it updated its phase 2b data from its Eteplirsen study. But the stock fell for the wrong reasons and should still be a strong buy. Here's why...
In this article: RNA, SRPT
Read

Latest Tweets for $RNA

No tweets yet!